NEMUS, Catalent to Advance NB1222 for Clinical Trials

NEMUS Bioscience, Inc. and partner Catalent Pharma Solutions will advance development of a human-dosage suppository formulation of NB1222, the prodrug of tetrahydrocannabinol (THC). NB1222, also known as THC-valine-hemisuccinate, is being developed for the treatment and management of chemotherapy-induced nausea and vomiting (CINV). NB1222 is synthetically manufactured and is not plant-derived.

"Nemus is looking forward to working with Catalent to complete this important milestone as the company prepares to advance the candidate therapy to human clinical trials," said Brian Murphy, M.D., chief executive officer and chief medical officer of Nemus. "In addition to the recognized anti-emetic activity of cannabinoids, we feel a formulation that could provide reliable and predictable bioavailability and pharmacokinetics, could leverage other valuable physiological attributes associated with cannabinoids like appetite stimulation along with anxiolytic and pain mitigation properties in a patient population that could benefit from these activities."

Dr. Aris Gennadios, president, Catalent Softgel Technologies said, "We believe Catalent's softgel technology is a great delivery choice for NB1222. With the convenience that softgel can offer, combined with a lipid formulation to enhance bioavailability and help assure dose uniformity, we expect Nemus to be well positioned to pursue development of an efficacious drug product."